Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$7.59 +0.2%	$7.92	$3.76 ▼ $46.80	$46.34M	2.77	174,398 shs	39,287 shs
BFRG Bullfrog AI	$1.26 -0.8%	$1.55	$1.23 ▼ $4.84	$11.87M	0.47	541,542 shs	111,574 shs
IPSC Century Therapeutics	$0.52 +6.2%	$0.58	$0.34 ▼ $2.05	$44.80M	1.78	720,942 shs	596,189 shs
PRLD Prelude Therapeutics	$0.81 -2.3%	$0.88	$0.61 ▼ $6.80	$45.62M	1.22	188,326 shs	164,481 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	-1.56%	-5.38%	-9.45%	+27.44%	-44.95%
BFRG Bullfrog AI	0.00%	-2.31%	-15.89%	-33.85%	-50.78%
IPSC Century Therapeutics	-3.49%	-13.33%	-18.44%	-6.92%	-71.53%
PRLD Prelude Therapeutics	-3.56%	-2.22%	+1.51%	-17.30%	-83.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALGS Aligos Therapeutics	4.2956 of 5 stars	3.5	4.0	4.8	3.0	1.7	0.0
BFRG Bullfrog AI	1.0484 of 5 stars	0.0	5.0	0.0	1.1	2.5	0.0
IPSC Century Therapeutics	2.6089 of 5 stars	3.5	5.0	0.0	0.0	1.7	0.6
PRLD Prelude Therapeutics	2.789 of 5 stars	3.5	4.0	0.0	0.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	3.00	Buy	$70.00	822.87% Upside
BFRG Bullfrog AI	0.00	N/A	N/A	N/A
IPSC Century Therapeutics	3.00	Buy	$3.75	621.15% Upside
PRLD Prelude Therapeutics	3.00	Buy	$4.50	456.93% Upside

Current Analyst Ratings Breakdown

Latest BFRG, PRLD, ALGS, and IPSC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/16/2025	IPSC Century Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$3.94M	11.76	N/A	N/A	($7.50) per share	-1.01
BFRG Bullfrog AI	$60K	197.82	N/A	N/A	$0.57 per share	2.21
IPSC Century Therapeutics	$6.59M	6.80	N/A	N/A	$1.90 per share	0.27
PRLD Prelude Therapeutics	$7M	6.52	N/A	N/A	$2.39 per share	0.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$131.21M	-$19.79	N/A	N/A	N/A	-2,337.24%	-22.41%	-12.09%	N/A
BFRG Bullfrog AI	-$6.99M	-$0.81	N/A	∞	N/A	N/A	-163.23%	-139.94%	8/13/2025 (Estimated)
IPSC Century Therapeutics	-$126.57M	-$0.29	N/A	N/A	N/A	-19.10%	-10.71%	-5.96%	8/14/2025 (Estimated)
PRLD Prelude Therapeutics	-$127.17M	-$1.69	N/A	N/A	N/A	N/A	-89.18%	-69.26%	N/A

Latest BFRG, PRLD, ALGS, and IPSC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	IPSC Century Therapeutics	-$0.38	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	ALGS Aligos Therapeutics	-$2.35	-$1.53	+$0.82	-$1.53	$0.43 million	$0.97 million
5/15/2025	Q1 2025	IPSC Century Therapeutics	-$0.31	$0.89	+$1.20	$0.89	$45.52 million	$109.16 million
5/13/2025	Q1 2025	BFRG Bullfrog AI	N/A	-$0.21	N/A	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
BFRG Bullfrog AI	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	6.31	6.31
BFRG Bullfrog AI	N/A	4.87	4.87
IPSC Century Therapeutics	N/A	11.70	11.70
PRLD Prelude Therapeutics	N/A	5.18	5.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
BFRG Bullfrog AI	0.96%
IPSC Century Therapeutics	50.20%
PRLD Prelude Therapeutics	79.72%

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	4.80%
BFRG Bullfrog AI	33.90%
IPSC Century Therapeutics	5.00%
PRLD Prelude Therapeutics	63.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	90	6.11 million	5.82 million	No Data
BFRG Bullfrog AI	4	9.42 million	6.22 million	Not Optionable
IPSC Century Therapeutics	170	86.16 million	81.85 million	Optionable
PRLD Prelude Therapeutics	120	56.46 million	20.38 million	Optionable

BFRG, PRLD, ALGS, and IPSC Headlines

Recent News About These Companies

Can Prelude Therapeutics (NASDAQ:PRLD) Afford To Invest In Growth?

August 11 at 9:52 AM | finance.yahoo.com

Prelude Therapeutics (PRLD) Projected to Post Earnings on Monday

August 10 at 2:43 AM | americanbankingnews.com

Prelude Therapeutics (NASDAQ:PRLD) Trading 2% Higher - Time to Buy?

July 26, 2025 | marketbeat.com

Prelude Therapeutics Incorporated (PRLD) - Yahoo Finance

June 25, 2025 | finance.yahoo.com

Prelude Therapeutics Incorporated (PRLD) - Yahoo Finance

June 25, 2025 | finance.yahoo.com

Prelude Therapeutics to Present at Major Healthcare Conferences in June 2025

June 3, 2025 | msn.com

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

June 2, 2025 | globenewswire.com

Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challenges

May 28, 2025 | investing.com

Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug

May 15, 2025 | fiercebiotech.comF

Prelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical Programs

May 10, 2025 | msn.com

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025 | globenewswire.com

Prelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025

May 4, 2025 | msn.com

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

May 1, 2025 | globenewswire.com

Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies

April 30, 2025 | msn.com

Prelude Announces Presentations at 2025 AACR Annual Meeting

April 25, 2025 | globenewswire.com

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know

April 10, 2025 | zacks.com

Prelude Therapeutics Founder Acquires 28% More Stock

March 29, 2025 | finance.yahoo.com

Prelude Therapeutics CEO buys $467K in common stock

March 28, 2025 | markets.businessinsider.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Buys $69,000.00 in Stock

March 28, 2025 | insidertrades.com

Prelude Therapeutics stock surges on insider buying

March 27, 2025 | investing.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Purchases 47,500 Shares

March 15, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRG, PRLD, ALGS, and IPSC Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$7.58 +0.02 (+0.20%)

As of 03:29 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Bullfrog AI NASDAQ:BFRG

$1.26 -0.01 (-0.79%)

As of 03:30 PM Eastern

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

Century Therapeutics NASDAQ:IPSC

$0.52 +0.03 (+6.21%)

As of 03:31 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Prelude Therapeutics NASDAQ:PRLD

$0.81 -0.02 (-2.30%)

As of 03:27 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time